Top entities: Atara Biotherapeutics, United States — Food and Drug Administration, Pomerantz LLP, United States — United States District Court for the Northern District of California, Pierre Fabre.

What category does this event fall under?

Business — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 12, 2026. Coverage continues to evolve.

Business class action

Atara Biotherapeutics Class Action Lawsuit

Q: When did this event occur?

First reported May 01, 2026; last updated May 12, 2026.

Q: What is the market impact?

Direct. The class action lawsuit against Atara Biotherapeutics, stemming from significant declines in its stock price due to repeated rejections of its lead drug candidate by the United States — Food and Drug Administration, indicates heightened regulatory scrutiny and potential financial liabilities for the company.

Analysis based on 8 articles · First reported May 01, 2026 · Last updated May 12, 2026

Sentiment

-70

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The class action lawsuit against Atara Biotherapeutics, stemming from significant declines in its stock price due to repeated rejections of its lead drug candidate by the United States — Food and Drug Administration, indicates heightened regulatory scrutiny and potential financial liabilities for the company. This event highlights the risks associated with pharmaceutical development and regulatory approval processes, potentially impacting investor confidence in the biotechnology sector. The negative sentiment surrounding Atara Biotherapeutics could lead to further stock price depreciation and affect its ability to fund operations, especially given its reliance on milestone payments from Pierre Fabre.

Biotechnology Pharmaceuticals Legal Services

Event Summary

Pomerantz LLP has filed a class action lawsuit against Atara Biotherapeutics and certain officers in the United States — United States District Court for the Northern District of California. The lawsuit alleges that Atara Biotherapeutics made materially false and misleading statements regarding its business, operations, and prospects, specifically concerning the regulatory approval of its lead product candidate, tabelecleucel. The complaint details that manufacturing issues and deficiencies in the ALLELE study made United States — Food and Drug Administration approval unlikely, leading to overstated regulatory prospects. The United States — Food and Drug Administration issued two Complete Response Letters on January 16, 2025, and January 12, 2026, and placed a clinical hold on Atara Biotherapeutics' Investigational New Drug applications on January 21, 2025. These events caused significant drops in Atara Biotherapeutics' stock price, with declines of 40.5%, 7.91%, and 56.99% respectively. The class period for the lawsuit is between May 20, 2024, and January 9, 2026.

Key Actions

100 Pomerantz LLP filed class action lawsuit Atara Biotherapeutics

95 United States — Food and Drug Administration issued Complete Response Letter Atara Biotherapeutics

90 United States — Food and Drug Administration issued Complete Response Letter Atara Biotherapeutics

70 Atara Biotherapeutics submitted Biologics License Application United States — Food and Drug Administration

Entities Involved

stock

Atara Biotherapeutics

Atara Biotherapeutics is the defendant in a class action lawsuit alleging false and misleading statements regarding its business, operations, and prospects, specifically concerning the regulatory approval of its lead product candidate, tabelecleucel. Its stock price experienced significant declines following FDA decisions.

Importance 100 Sentiment -90

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration issued Complete Response Letters and placed a clinical hold on Atara Biotherapeutics' Investigational New Drug applications, citing manufacturing issues and deficiencies in the ALLELE study, which directly impacted the company's stock price and led to the class action.

Importance 90 Sentiment 0

priv

Pomerantz LLP

Pomerantz LLP filed the class action lawsuit against Atara Biotherapeutics on behalf of investors, seeking to recover damages for alleged violations of federal securities laws.

Importance 80 Sentiment 70

govactor

United States — United States District Court for the Northern District of California

The United States — United States District Court for the Northern District of California is the venue where the class action lawsuit against Atara Biotherapeutics was filed and is being docketed.

Importance 60 Sentiment 0

priv

Pierre Fabre

Pierre Fabre is partnered with Atara Biotherapeutics for the commercialization of tabelecleucel and provides milestone payments, which are crucial for Atara Biotherapeutics' operations. The regulatory setbacks for tabelecleucel could affect these payments.

Importance 30 Sentiment 0

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard